White matter hyperintensities (WMHs) are frequently detected by MRI in the aging brain^[@R1]^ and are associated with a range of negative health outcomes.^[@R2][@R3][@R6]^ Prevalence ranges from 40% to 70% in the fifth decade^[@R7]^ and increases with age. It is important that Hispanics and African Americans have shown more severe WMHs than ancestral Europeans.^[@R8]^ Although heterogeneous in etiology, there is a consistent link between WMH burden and cerebrovascular risk factors, as well as with retinal microvascular abnormalities and vascular pathology.^[@R9]^ Thus, WMHs could be considered a quantitative marker of small vessel injury.^[@R10]^ Moreover, WMHs have a significant genetic component, with heritability estimates from 0.45 to 0.80.^[@R10][@R11][@R13]^

Identifying genetic determinants of WMHs has been a challenge. Linkage studies have yielded conflicting findings regarding the genetic loci influencing WMHs.^[@R12][@R13][@R14]^ The most consistently replicated locus identified for WMHs is on chromosome 17q25 and was first identified in ∼9,500 individuals of European descent.^[@R15]^ This locus was later replicated and additional loci on chromosomes 10q24 and 2p21 identified.^[@R16]^ A multiethnic meta-analysis, including ∼2,000 African Americans, ∼800 Hispanics, and ∼400 Asians, identified additional loci on chromosomes 1q22 and 2p16.^[@R16]^

Although Hispanics and African Americans show more severe WMHs than Europeans,^[@R8]^ these populations have not been the focus of genetic discovery. To address this, we performed a genome-wide association scan to identify genetic variants influencing WMHs in Hispanics in 2 community-based cohorts from the Northern Manhattan Study (NOMAS) and the Washington Heights--Inwood Columbia Aging Project (WHICAP).

METHODS {#s1}
=======

Participants. {#s1-1}
-------------

Hispanic participants from NOMAS and WHICAP with WMHs and genotype data available were included in this study. All participants provided written informed consent. The study was approved by the Institutional Review Boards of the University of Miami and Columbia University Medical Center. The research design and detailed ascertainment scheme for NOMAS and WHICAP were described in detail previously.^[@R17],[@R18]^ To be eligible for recruitment in the NOMAS, participants had to be at least 40 years of age, never been diagnosed with a stroke, and resided for at least 3 months in a household with a telephone in Northern Manhattan. A total of 3,298 participants were enrolled from 1993 to 2001, and 199 unrelated household members were recruited from 2003 to 2008. Data were collected at enrollment using standardized data collection instruments, medical records, and fasting blood samples.

For the WHICAP, participants were recruited in 2 waves (1992--1994 and 1999--2002) through the use of a probability sample of Medicare beneficiaries who were older than 65 years and residing in a defined area of Northern Manhattan. Each WHICAP participant underwent an in-person interview of general health and functional ability at the time of study entry, followed by a standardized assessment, including medical history, physical and neurologic examination, and a neuropsychological battery.

Quantitative measurement of WMH volume. {#s1-2}
---------------------------------------

Selected NOMAS and WHICAP participants were scanned on the same 1.5T Philips Intera scanner at Columbia University Medical Center using the same sequences. Participants were selected for MRI, on average 6 years after recruitment, if they were 55 years or older, were classified as nondemented at a previous study visit, had no contraindications for MRI, and signed informed consent.^[@R17],[@R18]^ Data sets were transferred electronically to UC Davis for morphometric analysis as previously described.^[@R19]^ Briefly, nonbrain elements were manually removed from the image by operator-guided tracing of the dura mater within the cranial vault, including the middle cranial fossa but excluding the posterior fossa and cerebellum. The resulting measure of the cranial vault was defined as the total intracranial volume. After image intensity nonuniformities were removed from the image, the corrected image was modeled as a mixture of 2 Gaussian probability functions with the segmentation threshold determined at the minimum probability between these 2 distributions. Once brain matter segmentation was achieved, a single Gaussian distribution was fitted to image data, and a segmentation threshold for WMHs was determined a priori as 3.5 SDs in pixel intensity above the mean of the fitted distribution of the brain parenchyma.^[@R20]^ For the NOMAS, high interrater reliabilities were documented for both the intracranial volume (0.97) and WMH (0.99).^[@R2]^

Genotyping, imputation, and quality control. {#s1-3}
--------------------------------------------

DNA samples were obtained through whole blood extraction. For the NOMAS, genotyping of DNA samples was performed using Affymetrix Genome-Wide Human SNP Array 6.0 chips according to Affymetrix procedures at the Genotyping Core of the John P. Hussman Institute for Human Genomics at the University of Miami. Genotype calling was performed using Affymetrix Power Tools v.1.15.0. For the WHICAP, genotyping was performed in 2 batches on the Illumina HumanHap 650Y (WHICAP1) and Omni 1M (WHICAP2) chips, according to Illumina procedures at Columbia University. Genotype calling was performed separately for WHICAP1 and WHICAP2 using GenomeStudio v.1.0. Genome-wide genotype data were available on a total of 1,067 Hispanics meeting all inclusion criteria from either NOMAS (811) or WHICAP (191 WHICAP1 and 65 WHICAP2). Because both NOMAS and WHICAP were sampled from Northern Manhattan, we expected some participants to be enrolled in both studies. Therefore, we checked for unexpected relationships with identical-by-descent proportion \>0.25 using PLINK^[@R21]^ and found 34 duplicate and 15 related pairs between NOMAS and WHICAP1 or WHICAP2. After dropping at least 1 from each pair, typically the one genotyped on the smaller array, a total of 1,019 unrelated individuals remained for the final joint analysis.

Quality control was applied to both DNA samples and single nucleotide polymorphisms (SNPs). Specifically, samples were removed from further analysis if they had call rates below 95%, sex discrepancies, relatedness, autosomal heterozygosity beyond 4 SDs from the mean. In addition, a subset of ∼51,000 independent SNPs (R^2^ ≤ 0.2) across the genome were used to infer principal components using Eigenstrat software.^[@R22]^ Samples were eliminated if they were outliers beyond 6 SDs from the mean based on the first 10 principal components. An additional 50 participants from the WHICAP with a diagnosis of stroke were excluded from further analysis. This led to 760, 97, and 65 samples available for analysis from NOMAS, WHICAP1, and WHICAP2, respectively. SNPs were excluded if they were not in the Hardy-Weinberg equilibrium (*p* \< 1 × 10^−6^) or had a genotyping call rate less than 95%. This led to a total of 813,769; 624,026; and 970,293 SNPs available in NOMAS, WHICAP1, and WHICAP2, respectively. A total of 6%, 1%, and 11% of SNPs were dropped because of low call rate for NOMAS, WHICAP1, and WHICAP2, respectively. Only ∼100,000 SNPs overlapped between all 3 data sets, so imputation was performed on each data set using IMPUTE2^[@R23]^ with the 1000 Genomes Phase I (interim) NCBI Build b37 (June 2011) reference panel. This reference panel included 1,094 individuals from across Europe, Africa, Asia, and the Americas. SNPs were subsequently removed if the imputation quality score was less than 0.8 or the minor allele frequency was less than 0.01 in any of the NOMAS, WHICAP1, or WHICAP2 samples, resulting in a total of 6,783,792 SNPs for analysis.

Statistical analyses. {#s1-4}
---------------------

To compare the sample characteristics between the NOMAS and WHICAP Hispanic cohorts, a χ^2^ test was used to test for frequency differences for categorical variables and a student *t* test was performed to test for mean or median differences for continuous variables using R.^[@R24]^ Population substructure was assessed using ADMIXTURE,^[@R25]^ including reference populations of Europeans (Utah residents with northern and western European ancestry) and Africans (Yoruba in Ibadan, Nigeria) from 1000 Genomes as well as Native Americans from the Human Genome Diversity Project.^[@R26]^ Because of the skewed distribution, WMHs were log transformed. To evaluate the association of WMHs with each SNP, using PLINK,^[@R21]^ an additive genetic model was fit by regressing log-transformed WMHs on genotype dosage (0--2 copies of the variant allele) after adjusting for age at MRI, sex, total intracranial volume, and the top 2 principal components of ancestry to account for population substructure. No adjustment for treatment was needed, as all patients were classified as nondemented. These analyses were performed separately in each of the NOMAS, WHICAP1, and WHICAP2 cohorts. An inverse-variance meta-analysis under a fixed-effects model was used in METAL (released March 27, 2011)^[@R27]^ to summarize results across the 3 strata. SNPs with I^2^ heterogeneity estimates greater than 50% were removed post hoc. VEGAS (v.01)^[@R28]^ was used to assign SNPs to genes (within 50KB using NCBI Build b37) and produce gene-based test statistics and empirical *p* values by simulation. A random sample of 200 Hispanics from the NOMAS was used to estimate linkage disequilibrium (LD) patterns for each gene.

To determine the relevance of our findings to other race and ethnic groups, summary statistics were obtained from CHARGE analyses of ∼18,000 Europeans, ∼2,000 African Americans, and ∼400 Asians^[@R16]^ for each of our top SNPs from the single SNP analysis (using an a priori threshold of *p* \< 1 × 10^−5^ and independence with R^2^ ≤ 0.2 based on an LD-clumping procedure) and each SNP within our top genes (using an a priori threshold of *p* \< 1 × 10^−3^). Although the CHARGE analyses^[@R16]^ included ∼800 Hispanics, these samples overlapped largely with NOMAS and WHICAP and therefore did not provide a suitable and independent replication of our study. A multiethnic meta-analysis was performed using a z-score--based fixed-effects model in METAL (released March 27, 2011). An inverse-variance meta-analysis was not possible, given the data format produced by the previous CHARGE z-score--based meta-analyses.

VEGAS2 (v.02)^[@R29]^ was used to produce gene-based empirical *p* values from the CHARGE summary statistics using 1000 Genomes reference panels of Europeans, Africans, and Asians to estimate LD patterns for each gene. While VEGAS allows input of a customized reference data set to estimate LD (necessary for our Hispanic cohorts), VEGAS2 does not allow this option. VEGAS2 does, however, provide more extensive reference panel data than VEGAS for the analysis of the European, African American, and Asian samples used in the CHARGE analyses. Nonetheless, the VEGAS and VEGAS2 algorithms are based on the same simulation strategy and produce similar results, given the same input data set. Sensitivity analyses were conducted using MAGMA (v.1.06),^[@R30]^ which produced similar results (data not shown).

RESULTS {#s2}
=======

The sample characteristics of the NOMAS and WHICAP Hispanic MRI cohorts are presented in [table 1](#T1){ref-type="table"}. Among the 922 Hispanic participants overall, the mean age was 71.1 ± 9.0 years, and 63.7% were women. Compared with NOMAS Hispanic participants, WHICAP Hispanic participants had a greater WMH volume (WMHV) and smaller intracranial volumes because of the older age distribution. The population substructure of each of the NOMAS and WHICAP Hispanic MRI cohorts is presented in [figure 1](#F1){ref-type="fig"}. The overall cohort was on average 57% European, 31% African, and 12% Native American, expected, given the largely Dominican Hispanic population of Northern Manhattan.

###### 

WMH measures and associated risk factors

![](NG2017005306TT1)

![Global genetic ancestry\
The plots depict the ancestral proportions observed within each cohort, where individual is represented on the x-axis and proportion ancestry on the y-axis. Global ancestry was calculated using 50,327 independent single nucleotide polymorphisms (R^2^ ≤ 0.2), with reference populations including 46 Europeans (Utah residents with northern and western European ancestry from 1000 Genomes), 46 Africans (Yoruba in Ibadan, Nigeria from 1000 Genomes), and 46 Native Americans (Surui and Karitiana of Brazil and Maya and Pima of Mexico from the Human Genome Diversity Project). NOMAS = Northern Manhattan Study; WHICAP = Washington Heights--Inwood Columbia Aging Project.](NG2017005306FF1){#F1}

In the meta-analysis of Hispanic samples, the quantile-quantile plot (figure e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000185)) did not reveal an obvious departure from the distribution of expected *p* values by chance (genomic inflation factor \[λ\] of 0.997), suggesting no significant inflation of probability values due to population substructure. Genome-wide association results are shown in [figure 2](#F2){ref-type="fig"}. While no SNP reached genome-wide significance, 17 independent SNPs (R^2^ ≤ 0.2) were associated with WMHV at *p* \< 1 × 10^−5^. Frequencies and effect estimates for these 17 SNPs are shown in [table 2](#T2){ref-type="table"}. The mean changes in ln(WMHV) for per copy increase in these risk alleles ranged from 0.14 to 0.55, corresponding to 14.4%--21.7% of the mean WMHV. Seven of the 17 SNPs were within a known gene. While none of the 17 SNPs demonstrated statistical significance at a multiple testing threshold of 2.9 × 10^−3^ (0.05/17), one of these 17 SNPs, rs9957475 (risk allele = C, beta = 0.188, *p* = 6.19 × 10^−6^) located in GATA-binding protein 6 (*GATA6*), demonstrated evidence of association with *p* \< 0.05 in an independent sample of African Americans (rs9957475, risk allele = C, *p* = 0.020). In the NOMAS Hispanic sample, the average WMHV for 0, 1, and 2 copies of the risk allele were 6.08, 8.58, and 8.95 mL, respectively. No SNPs reached genome-wide significance in the z-score--based or sample size--weighted, multiethnic meta-analysis, not surprising given the substantial weight (per the sizable sample) of the largely insignificant European cohort.

![Single nucleotide polymorphism association results for meta-analysis of white matter hyperintensity volume\
The Manhattan plot depicts the --log 10 *p* values by position from the Hispanic meta-analysis of Northern Manhattan Study and Washington Heights--Inwood Columbia Aging Project single single nucleotide polymorphism association results.](NG2017005306FF2){#F2}

###### 

Single SNP association results (independent with R^2^ \< 0.2) with *p* ≤ 1.0 × 10^−5^ among Hispanics
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Using RegulomeDB,^[@R31]^ we sought to determine whether any SNP associated with WMHV had regulatory function. Of the 95 SNPs with *p* \< 1 × 10^−5^ (17 independent SNPs with R^2^ ≤ 0.2), 5 were likely to affect protein binding: one of these variants, rs2670314, was located downstream of GDNF family receptor α 4 (*GFRA4*) on chromosome 20p13, while the remaining 4 variants (rs73306471, rs73306449, rs73306445, and rs73306424) were located on chromosome 20q13 within an LD block spanning 3 genes, including WAP four-disulfide core domain 3 (*WFDC3*), deoxynucleotidyltransferase terminal-interacting protein 1 (*DNTTIP1*), and ubiquitin-conjugating enzyme E2 C (*UBE2C*). In total, these 5 SNPs were predicted to influence the binding of 70 proteins. A list of the proteins affected by each SNP and associated RegulomeDB scores are shown in table e-1. Notably, Spi-1 proto-oncogene (*SPI1*) was the only protein influenced by rs2670314 on 20q13 and rs73306449 on 20p13. Two additional SNPs within the *WFDC3-DNTTIP1-UBE2C* LD block influenced the binding of *SPI1*. No other proteins were influenced by 4 or more SNPs. Of the 6,395 SNPs with *p* \< 1 × 10^−3^, 110 were likely to affect the binding of 130 proteins (table e-1). The most commonly affected proteins were RNA polymerase II subunit A (*POLR2A*), which was influenced by 24 variants across 12 chromosomes, and CCCTC-binding factor (*CTCF*), which was influenced by 23 variants across 13 chromosomes (table e-2).

[Table 3](#T3){ref-type="table"} indicates the results from our gene-based association tests (*p* \< 1.00 × 10^−3^). The most strongly associated gene in our Hispanic sample, *UBE2C* (*p* = 3.61 × 10^−4^), demonstrated evidence of association in the African American sample (*p* = 0.034). The single SNP results of all variants within this gene region in the Hispanic and all replication samples are shown in table e-3. The majority of SNPs within 50KB of *UBE2C* with *p* \< 1.00 × 10^−5^ in Hispanics were monomorphic in the European and Asian samples.

###### 

Gene-based association results with *p* ≤ 1.0 × 10^−3^ among Hispanics

![](NG2017005306TT3)

DISCUSSION {#s3}
==========

In this genome-wide association study (GWAS) of 2 community-based Hispanic cohorts, 17 independent SNPs located within 7 genes showed suggestive associations with WMHV with *p* \< 1 × 10^−5^. One SNP in *GATA6* demonstrated evidence of association in an independent sample of African Americans. A total of 110 unique variants with *p* \< 1 × 10^−3^ were shown to influence the binding of 130 unique proteins, most commonly *CTCF* and *POLR2A.* Four of 5 of the 110 variants with *p* \< 1 × 10^−5^, all on chromosomes 20q13 and 20p13, influenced the binding of *SPI1*. A gene-based analysis implicated *UBE2C* on chromosome 20q13 in our Hispanic sample, a finding which was supported in an independent sample of African Americans. This study focuses on a minority population as a means of discovery for novel genetic variants that influence white matter lesion burden.

*GATA6* encodes a member of the GATA family of transcription factors and has been shown to regulate angiogenesis and promote survival of endothelial cells.^[@R32]^ Expression in early embryogenesis is crucial to heart development, and mutations in this gene have been shown to be associated with a number of congenital abnormalities including dilated cardiomyopathy^[@R33]^ and atrial fibrillation.^[@R34]^ In addition to *GATA6* displaying a single SNP association with WMHV in Hispanics and African Americans, 18 variants with *p* \< 1 × 10^−3^ in the Hispanic analysis affect the binding of at least 1 of *GATA6*, *GATA1*, *GATA2*, and *GATA3*. Similar to *GATA6*, the other members of the GATA family of transcription factors are important in the vascular and lymphatic systems through regulation in the development of erythrocytes (*GATA1*) and lymphocytes (*GATA2* and *GATA3*).^[@R35]^

Other notable transcription factors affected by our top SNP associations include *CTCF* and *POLR2A*. *CTCF* is a regulator protein, which can bind histone acetyltransferase--containing complex or histone deacetylase (HDAC)-containing complex, functioning as a transcriptional activator or repressor. Protein acetylation has been implicated in a host of neurologic diseases in recent years due primarily to HDAC-associated decrease in the level of a protein or widespread genomic transcriptional losses.^[@R36]^ Thus, *CTCF* also plays a critical role in this pathway for neurodegeneration. *POLR2A* plays a role in messenger RNA (mRNA) processing through the transcription of pre-mRNA from the genomic DNA; thus, inhibition of *POLR2A* binding could also lead to widespread RNA dysregulation, an integral element in a number of neurologic disease.^[@R37]^

Perhaps, one of the most interesting findings in this study is the implication of *UBE2C* in the gene-based test for both Hispanics and African Americans. This ubiquitin-conjugating enzyme is an important regulator in cell cycle progression, and overexpression has been associated with progression of malignant gliomas.^[@R38]^ There is a substantial amount of LD in Hispanics between SNPs within 50KB of *UBE2C*, including SNPs in *WFDC3, DNTTIP1*, *TNNC2*, *SNX21*, *ACOT8*, and *ZSWIM3*. *WFDC3* functions as a protease inhibitor, and notably, both protein degradation though ubiquitination and protease inhibition are represented among neurodegenerative diseases.^[@R39]^ Furthermore, *DNTTPI1* acts as a chromatin-binding module in complex with *HDAC1* and *HDAC2*. As previously mentioned, 3 SNPs with *p* \< 1 × 10^−5^ within *WFDC3* and *DNTTIP1* on chromosome 20q13 affect protein binding of *SPI1*, with both genes also showing nominal significance in Hispanics with *p* = 9.55 × 10^−3^ and *p* = 2.40 × 10^−3^, respectively. This is a transcription factor which is involved in the activation of gene expression during myeloid and B-lymphocyte development and is critical for viability and function of human brain microglia, with a loss reducing the ability of microglia to clear debris by phagocytosis.^[@R40]^ Outside chromosome 20q13, 1 additional SNP on chromosome 20p13 with *p* \< 1 × 10^−5^ and 7 additional SNPs with *p* \< 1 × 10^−3^ across 5 additional chromosomes affect binding of *SPI1*.

The CHARGE consortium identified loci for WMHV on chromosomes 17q25, 10q24 2p21, 1q22, and 2p16 in primarily individuals of European descent but also through multiethnic meta-analysis and replication, inclusive of ∼2,000 African Americans, ∼400 Asians, in addition to the ∼18,000 Europeans (which we have now used as replication of our findings) and ∼800 Hispanics (a majority subset of our NOMAS and WHICAP samples).^[@R16]^ Only 2 of these loci (*PDCD11* on 10q24 and *PMF1* on 1q22) demonstrated a nominal level of significance (*p* \< 0.05) in the Hispanic sample, with the same risk allele as seen in Europeans. This may be due to differences in allele frequency across populations and supports the importance of genetic discovery in minority populations. However, SNPs implicated by CHARGE within 17q25, 10q24, and 2p16 have been shown to influence binding of 30 proteins,^[@R30]^ 29 of which are also influenced by SNPs with *p* \< 1 × 10^−3^ in the Hispanic analysis, most notably *POLR2A*. This may indicate common pathways across populations.

A strength of the current study is that it focuses on discovery of novel variation influencing WMHV in a Hispanic sample. It includes analysis of 2 community-based cohorts which used the same MRI protocol and quantitative measurement of WMHV at the same medical center. However, our study also has limitations. First, with 922 Hispanic participants, we had limited power, at a genome-wide significance level, to uncover an association with small-to-moderate effect sizes. Second, as comprehensive genotype data are not available for Hispanic populations in the 1000 Genome database, imputations were based on pooled samples from populations of the Americas, Europe, Africa, and Asia. Bias in allele frequency estimates cannot be excluded for those SNPs with large allele differences across subpopulations, although high imputation quality was observed. Third, since this GWAS was performed in Hispanics, findings may not necessarily extend to other race-ethnic groups. For instance, we see varying allele frequency differences across notable SNPs such as the one found in *GATA6*. The majority of SNPs we see as associated in Hispanics within 50KB of *UBE2C* are in fact monomorphic in the European and Asian replication samples, findings which are underscored by the population substructure observed in our study sample. This is a weakness for generalizability but emphasizes the importance of genetic study in diverse samples.

This GWAS of 2 community-based Hispanic cohorts revealed several novel genetic loci for WMHV. Further replication is needed in an independent Hispanic sample as well as samples from additional race/ethnic groups. In addition, local ancestry computation may provide additional insight into the ancestral risk haplotypes. While fine mapping is needed to pinpoint causal variation for drug targets in relevant populations, this study represents progress toward elucidating the genetic underpinnings of increased WMHV potentially underlying cognitive impairment and vascular dementia.
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